scholarly journals Faculty Opinions recommendation of The association between antidepressant treatment and brain connectivity in two double-blind, placebo-controlled clinical trials: a treatment mechanism study.

2019 ◽  
Author(s):  
Gregory Fonzo
Keyword(s):  
Clinical Trials ◽  
Antidepressant Treatment ◽  
Brain Connectivity ◽  
Mechanism Study ◽  
Controlled Clinical Trials ◽  
Double Blind ◽  
Double Blind Placebo

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials

2008 ◽  
Vol 10 (2) ◽  
pp. 323-333 ◽  
Author(s):  
Joseph R Calabrese ◽  
Russell F Huffman ◽  
Robin L White ◽  
Suzanne Edwards ◽  
Thomas R Thompson ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Acute Treatment ◽  
Bipolar Depression ◽  
Controlled Clinical Trials ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2

2020 ◽  
Vol 7 (7) ◽  
Author(s):  
Joshua T Schiffer ◽  
Christine Johnston ◽  
Anna Wald ◽  
Lawrence Corey
Keyword(s):  
Clinical Trials ◽  
Severe Acute Respiratory Syndrome ◽  
Viral Infections ◽  
Controlled Clinical Trials ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Antiviral Therapies ◽  
Hospitalization Rates ◽  
Lower Likelihood ◽  
Golden Opportunity

Abstract As coronavirus disease 2019 cases and deaths continue to expand globally, there is an urgent need to develop, test, and approve effective antiviral therapies. Currently, a majority of clinical trials are evaluating therapies in patients who are already hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection. Given that the median time between development of symptoms and need for hospitalization is 1 week, a golden opportunity to intervene early is being missed. Indeed, for many other viral infections, early treatment soon after development of symptoms is associated with decreased mortality, lower hospitalization rates, and lower likelihood of transmission to others. In this study, we advocate for randomized, double-blind, placebo controlled, clinical trials to evaluate promising agents early during SARS CoV-2 infection.

Sign in / Sign up

Export Citation Format

Share Document